This topic contains a solution. Click here to go to the answer

Author Question: A metal has a Fermi level of 5.50 eV. At 1200 K, what energy will have a 90 occupancy probability? ... (Read 48 times)

mynx

  • Hero Member
  • *****
  • Posts: 555
A metal has a Fermi level of 5.50 eV. At 1200 K, what energy will have a 90 occupancy probability?
 
  A)
 
  5.79 eV
  B)
 
  5.73 eV
  C)
 
  5.56 eV
  D)
 
  5.44 eV
  E)
 
  5.27 eV

Question 2

If one metal has double the number of conduction electrons per unit volume of a second metal, then its Fermi level is how many times that of the second metal?
 
  A)
 
  1.41
  B)
 
  2.83
  C)
 
  2.00
  D)
 
  3.22
  E)
 
  1.59



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

elyse44

  • Sr. Member
  • ****
  • Posts: 319
Answer to Question 1

E

Answer to Question 2

E




mynx

  • Member
  • Posts: 555
Reply 2 on: Jul 29, 2018
Thanks for the timely response, appreciate it


jojobee318

  • Member
  • Posts: 298
Reply 3 on: Yesterday
Gracias!

 

Did you know?

The first successful kidney transplant was performed in 1954 and occurred in Boston. A kidney from an identical twin was transplanted into his dying brother's body and was not rejected because it did not appear foreign to his body.

Did you know?

Egg cells are about the size of a grain of sand. They are formed inside of a female's ovaries before she is even born.

Did you know?

About 3% of all pregnant women will give birth to twins, which is an increase in rate of nearly 60% since the early 1980s.

Did you know?

Though newer “smart” infusion pumps are increasingly becoming more sophisticated, they cannot prevent all programming and administration errors. Health care professionals that use smart infusion pumps must still practice the rights of medication administration and have other professionals double-check all high-risk infusions.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library